Active Clinical Trials
Numerous clinical trials are always active (i.e., open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. This section of the website contains a searchable list of all active trials. On the table below, hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword. To access more information about a particular trial, click on the trial ID.
| Cancer Type | Target Patient Population | Trial ID/More Info | Study Type | ECOG-ACRIN Oversight Committee(s) |
|---|---|---|---|---|
| Various | Metastatic (advanced) solid tumors, lymphomas, or myeloma and also rare cancer types with no standard treatment available | EAY131 / NCI-MATCH | Treatment | Developmental Therapeutics |
| Any | Ages 18-39 with any type of cancer except basal cell carcinoma | EAQ202 | Observation (Patient Reporting) | Cancer Control and Survivorship Committee and its Patient-Reported Outcomes Working Group; Health Equity Committee and its Adolescent and Young Adult Oncology Subcommittee |
| Any | Current smokers wanting to stop | EAQ171CD | Observation (Counseling) | Cancer Care Delivery Research |
| Any | Cancer patients with pneumonitis (lung inflammation) | EAQ172 | Treatment | Cancer Control and Survivorship |
| Anus | Metastatic (advanced), not able to be removed by surgery (inoperable) | EA2176 | Treatment | Gastrointestinal |
| Anus | Squamous cell type, no prior treatment | EA2182 / DECREASE | Treatment | Gastrointestinal |
| Bile Duct | Metastatic (advanced) cholangiocarcinoma | EA2187 | Treatment | Gastrointestinal |
| Blood | Acute lymphoblastic leukemia (ALL) | EA9152 | Treatment | Leukemia |
| Blood | Acute lymphoblastic leukemia (ALL) | EA9181 | Treatment | Leukemia |
| Blood | Acute lymphoblastic leukemia (ALL), T-cell Type | EA9213 | Treatment | Leukemia |
| Blood | Chronic myelogenous leukemia (CML) | EA9171 / BLAST MRD CML 1 | Treatment | Leukemia |
| Blood | Hodgkin lymphoma | E4412 | Treatment | Lymphoma |
| Blood | Mantle cell lymphoma | EA4151 | Treatment | Lymphoma |
| Blood | Mantle cell lymphoma | EA4181 | Treatment | Lymphoma |
| Blood | Myeloma, newly diagnosed | EAA181 / EQUATE | Treatment | Myeloma |
| Blood | Smoldering myeloma | EAA173 / DETER-SMM | Treatment | Myeloma |
| Blood | Previously diagnosed with multiple myeloma and on lenalidomide | EAA171 / OPTIMUM | Treatment | Myeloma |
| Blood | Acute myeloid leukemia with FLT3 mutation | PrE0905 | Treatment | N/A (PrECOG) |
| Blood | Suspected myelodysplastic syndromes | NHLBI-MDS / The National MDS Study | Screening/Early Detection | Leukemia |
| Bladder | Has spread to the lymph nodes | EA8185 / INSPIRE | Treatment | Genitourinary |
| Brain | Recurrent glioblastoma | EAF151 | Treatment | Brain Cancer Working Group |
| Breast | Women planning for regular mammograms | EA1151 / TMIST | Screening/Early Detection | Imaging; Prevention; Breast |
| Breast | HER2 positive type | EA1181 / CompassHER2 pCR | Treatment | Breast |
| Breast | Metastatic (advanced) with bone or mostly bone disease | EA1183 / FEATURE | Imaging | Breast |
| Breast | Women who decline the TMIST breast cancer screening trial | EAQ201 | Observation (Patient Reporting)) | Cancer Control and Survivorship |
| Esophagus | Locally advanced, able to be removed by surgery (operable) | EA2174 | Treatment | Gastrointestinal |
| Esophagus and Stomach | Metastatic (advanced), HER2 negative type | EA2183 | Treatment | Gastrointestinal |
| Gallbladder | Discovered at time of surgery to remove the gallbladder | EA2197 / OPT-IN | Treatment | Gastrointestinal |
| Head and Neck | p53-mutated squamous cell type, after surgery | EA3132 | Treatment | Head and Neck |
| Head and Neck | Squamous cell carcinoma of the head and neck that has come back after initial therapy | EA3191 | Treatment | Head and Neck |
| Head and Neck | Metastatic (advanced) squamous cell type that has returned after treatment with immune checkpoint inhibitors | EA3202 | Treatment | Head and Neck |
| Kidney or Thyroid | Blood pressure management | EAQ191 / CARISMA | Treatment | Cancer Control and Survivorship |
| Liver | Metastatic (advanced) or not able to be removed by surgery (inoperable) | EA2205 | Treatment | Gastrointestinal |
| Lung | Non-small cell type, metastatic (advanced) | EA5162 | Treatment | Thoracic |
| Lung | Non-small cell type, metastatic (advanced) | EA5163 / S1709 / INSIGNA | Treatment | Thoracic |
| Lung | Non-small cell type, not able to be removed by surgery (inoperable) | EA5181 | Treatment | Thoracic |
| Lung | Non-small cell type, metastatic (advanced) | EA5182 | Treatment | Thoracic |
| Lung | Non-small cell, non-squamous type | EA5191 | Treatment | Thoracic |
| Lung | Non-small cell type, able to be removed by surgery (operable) | E4512, an ALCHEMIST Trial | Treatment | Thoracic |
| Melanoma (Skin) | Metastatic (advanced) | EA6141 | Treatment | Melanoma |
| Melanoma (Skin) | Merkel cell type | EA6174 / STAMP | Treatment | Melanoma |
| Melanoma (Skin) | Advanced, BRAF V600E or BRAF V600K type, and elevated LDH | EA6191 / BAMM2 | Treatment | Melanoma |
| Melanoma (Skin) | Metastatic (advanced) | EA6192 / PET-Stop | Treatment | Melanoma |
| Melanoma (Skin) | Able to be removed by surgery (operable) | EA6194 | Treatment | Melanoma |
| Mesothelioma | Advanced pleural | PrE0506 / DREAM3R6 | Treatment | N/A (PrECOG) |
| Nose and Sinus | Squamous cell type, able to be removed by surgery | EA3163 | Treatment | Head and Neck |
| Pancreas | Patients with non-cancerous pancreas cysts | EA2185 | Screening/Early Detection | Gastrointestinal |
| Pancreas | Metastatic (advanced), older (aged 70+) | EA2186 / GIANT | Treatment | Gastrointestinal; Geriatric Oncology Working Group |
| Pancreas | Has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation | EA2192 / APOLLO | Treatment | Gastrointestinal |
| Penis | Metastatic (advanced) | EA8134 / InPACT | Treatment | Genitourinary |
| Prostate | Newly diagnosed, before surgery | EA8171 | Imaging/Treatment Planning | Genitourinary |
| Prostate | Within 6 weeks of surgery (radical prostatectomy) and at highest risk of progression to metastatic (advanced) stage | EA8183 / ERADICATE | Treatment | Genitourinary |
| Prostate | On close monitoring; at low risk of progressing | EA8184 | Prevention | Genitourinary |
| Prostate | Has come back after surgery | EA8191 / INDICATE | Treatment | Genitourinary |
| Rectum | Locally advanced, MSI-H or dMMR type | EA2201 | Treatment | Gastrointestinal |
| Throat | HPV positive type | EA3161 | Treatment | Head and Neck |
| Upper Urinary Tract | High grade (aggressive) | EA8192 | Treatment | Genitourinary |